Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Renovaro Inc (RENB)

Renovaro Inc (RENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program GlobeNewswire - Mon Dec 23, 8:00AM CST

RENB : 1.0300 (-8.04%)
Renovaro Regains Compliance with NASDAQ Listing Requirement GlobeNewswire - Fri Dec 20, 2:40PM CST

RENB : 1.0300 (-8.04%)
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection GlobeNewswire - Fri Dec 20, 8:00AM CST

RENB : 1.0300 (-8.04%)
Renovaro: Fiscal Q1 Earnings Snapshot AP - Fri Nov 15, 4:27AM CST

Renovaro: Fiscal Q1 Earnings Snapshot

RENB : 1.0300 (-8.04%)
Renovaro Issues Shareholder Letter and Provides Corporate Update GlobeNewswire - Mon Nov 4, 7:31AM CST

RENB : 1.0300 (-8.04%)
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing GlobeNewswire - Thu Oct 17, 8:15AM CDT

RENB : 1.0300 (-8.04%)
Renovaro Announces Strategic Restructuring and Leadership Transition GlobeNewswire - Wed Oct 16, 8:28AM CDT

RENB : 1.0300 (-8.04%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 FinancialNewsMedia - Fri May 24, 7:45AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 0.9700 (+7.09%)
ONC.TO : 1.41 (+9.30%)
RENB : 1.0300 (-8.04%)
CYTO : 0.3000 (-25.94%)
PFE : 26.74 (+0.11%)
ABBV : 180.00 (+0.90%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 GlobeNewswire - Fri May 24, 7:45AM CDT

ONCY : 0.9700 (+7.09%)
ONC.TO : 1.41 (+9.30%)
RENB : 1.0300 (-8.04%)
CYTO : 0.3000 (-25.94%)
PFE : 26.74 (+0.11%)
ABBV : 180.00 (+0.90%)
Renovaro BioSciences (NASDAQ: RENB) Announces Results of Special Meeting Investor Brand Network - Fri Jan 26, 9:50AM CST

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held...

RENB : 1.0300 (-8.04%)

Barchart Exclusives

Unusual Options Volume in Palantir Puts Could Signal a Stock Peak Barchart - 1 hour ago
A huge, unusual volume in Palantir Technologies put options may signal a near-term peak in PLTR stock. It has doubled since its Q3 earnings on Nov. 4. However, put premiums are now very high—an income play for short-sellers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot